Understanding Endometrial Cancer: Causes, Stages, and Treatment Options

Endometrial cancer is a type of cancer that affects the lining of the uterus. It is the most common female genital cancer in the developing world, and an estimated 3% of women in developed countries will be diagnosed with this malignancy at some point in their lifetime. Here are some key points to understand about endometrial cancer:

Causes:
– It is more common among women using progestogen-containing oral contraceptives.
– Non-hormonal uterine devices have also been found to be strongly protective.
– There are two pathogenic types of endometrial cancer, one of which is associated with obesity, hyperlipidaemia, signs of hyperoestrogenism, and other disease states.

Stages:
– The FIGO staging system is used to determine the stage of endometrial cancer.
– Staging is the most important prognostic factor.
– The earlier endometrial cancer is diagnosed, the higher the rate of survival at 5 years.

Treatment:
– Standard management of endometrial cancer at diagnosis involves surgery, followed by chemotherapy with or without radiation therapy.
– It is most effectively treated by a combination of radiotherapy and hormone-based chemotherapy.
– The prognosis varies depending on the stage and type of endometrial cancer.

Overall, understanding the causes, stages, and treatment options for endometrial cancer is important for early detection and effective management of this malignancy.

Differential Diagnosis of a Woman with Acne and Infertility

Polycystic ovarian syndrome (PCOS), endogenous Cushing’s syndrome, Addison’s disease, congenital adrenal hyperplasia (CAH), and primary hypoparathyroidism are all potential differential diagnoses for a woman presenting with acne and infertility. PCOS is the most likely diagnosis, as it presents with menstrual dysfunction, anovulation, and signs of hyperandrogenism, including excess terminal body hair in a male distribution pattern, acne, and male-pattern hair loss. Endogenous Cushing’s syndrome and primary hypoparathyroidism are less likely, as they do not present with acne and infertility. Addison’s disease is characterized by hyperpigmentation, weakness, fatigue, poor appetite, and weight loss, while CAH may present with oligomenorrhoea, hirsutism, and/or infertility.

Treatment is administered based on the individual’s exposure to the infection rather than confirmed infection.

Chlamydia is a common sexually transmitted infection caused by Chlamydia trachomatis. It is prevalent in the UK, with approximately 1 in 10 young women affected. The incubation period is around 7-21 days, but many cases are asymptomatic. Symptoms in women include cervicitis, discharge, and bleeding, while men may experience urethral discharge and dysuria. Complications can include epididymitis, pelvic inflammatory disease, and infertility.

Traditional cell culture is no longer widely used for diagnosis, with nuclear acid amplification tests (NAATs) being the preferred method. Testing can be done using urine, vulvovaginal swab, or cervical swab. Screening is recommended for sexually active individuals aged 15-24 years, and opportunistic testing is common.

Doxycycline is the first-line treatment for Chlamydia, with azithromycin as an alternative if doxycycline is contraindicated or not tolerated. Pregnant women may be treated with azithromycin, erythromycin, or amoxicillin. Patients diagnosed with Chlamydia should be offered partner notification services, with all contacts since the onset of symptoms or within the last six months being notified and offered treatment.

Fat necrosis is a condition where local fat undergoes saponification, resulting in a benign inflammatory process. It is becoming more common due to breast-conserving surgery and mammoplasty procedures. Trauma or nodular panniculitis are common causes, with trauma being the most frequent. It is more prevalent in women with large breasts and tends to occur in the subareolar and periareolar regions. The breast mass is usually firm, round, and painless, but there may be a single or multiple masses. It may be tender or painful in some cases, and the skin around the lump may be red, bruised, or dimpled. A biopsy may be necessary to differentiate it from breast cancer.

Bacterial vaginosis is a condition characterized by the excessive growth of mainly bacteria.

Bacterial vaginosis (BV) is a condition where there is an overgrowth of anaerobic organisms, particularly Gardnerella vaginalis, in the vagina. This leads to a decrease in the amount of lactobacilli, which produce lactic acid, resulting in an increase in vaginal pH. BV is not a sexually transmitted infection, but it is commonly seen in sexually active women. Symptoms include a fishy-smelling vaginal discharge, although some women may not experience any symptoms at all. Diagnosis is made using Amsel’s criteria, which includes the presence of thin, white discharge, clue cells on microscopy, a vaginal pH greater than 4.5, and a positive whiff test. Treatment involves oral metronidazole for 5-7 days, with a cure rate of 70-80%. However, relapse rates are high, with over 50% of women experiencing a recurrence within 3 months. Topical metronidazole or clindamycin may be used as alternatives.

Bacterial vaginosis during pregnancy can increase the risk of preterm labor, low birth weight, chorioamnionitis, and late miscarriage. It was previously recommended to avoid oral metronidazole in the first trimester and use topical clindamycin instead. However, recent guidelines suggest that oral metronidazole can be used throughout pregnancy. The British National Formulary (BNF) still advises against using high-dose metronidazole regimes. Clue cells, which are vaginal epithelial cells covered with bacteria, can be seen on microscopy in women with BV.

If blood glucose targets are not achieved through diet and metformin in gestational diabetes, insulin should be introduced.

The patient in this case was diagnosed with gestational diabetes during their initial appointment. Despite attempting metformin, their fasting and two-hour post glucose challenge blood glucose levels remain elevated above the normal range. Therefore, insulin should be added to their treatment plan. Choosing to make no changes to their treatment plan is not the correct answer, as this could lead to increased risks for the fetus, such as the development of polyhydramnios or macrosomia. While referral for dietary and exercise regimens may be considered, this is likely to be a first-line intervention, and further escalation of medical therapy is necessary for the health of the fetus. Increasing the dose of metformin is not the correct answer, as the NICE guidelines recommend starting insulin when initial interventions have been unsuccessful. Waiting two weeks to repeat the results would delay necessary treatment intensification, which is required at the current clinic appointment.

Gestational diabetes is a common medical disorder affecting around 4% of pregnancies. Risk factors include a high BMI, previous gestational diabetes, and family history of diabetes. Screening is done through an oral glucose tolerance test, and diagnostic thresholds have recently been updated. Management includes self-monitoring of blood glucose, diet and exercise advice, and medication if necessary. For pre-existing diabetes, weight loss and insulin are recommended, and tight glycemic control is important. Targets for self-monitoring include fasting glucose of 5.3 mmol/l and 1-2 hour post-meal glucose levels.

The Mirena intrauterine system is approved for use as the progesterone component of hormone replacement therapy for a duration of 4 years. In a woman with a uterus, hormone replacement therapy aims to replace oestrogen to alleviate menopausal symptoms, but an additional source of progesterone is required to counteract the effects of unopposed oestrogen on the uterus, which increases the risk of endometrial hyperplasia and malignancy. As this patient already has the Mirena coil in place, which releases progesterone locally to act on the uterus, the only necessary treatment is oestrogen. Estradiol is the only option that provides only oestrogen therapy and can be administered topically or transdermally. Combined HRT, which includes both oestrogen and progesterone, would be inappropriate as the patient is already receiving progesterone from the Mirena coil. Levonorgestrel and medroxyprogesterone are both progesterones and would not provide oestrogen supplementation to the patient, which is necessary to alleviate her menopausal symptoms.

Managing Menopause: Lifestyle Modifications, Hormone Replacement Therapy, and Non-Hormone Replacement Therapy

Menopause is a natural biological process that marks the end of a woman’s reproductive years. It is diagnosed when a woman has not had a period for 12 consecutive months. Menopausal symptoms are common and can last for up to 7 years, with varying degrees of severity and duration. The management of menopause can be divided into three categories: lifestyle modifications, hormone replacement therapy (HRT), and non-hormone replacement therapy.

Lifestyle modifications can help manage menopausal symptoms such as hot flushes, sleep disturbance, mood changes, and cognitive symptoms. Regular exercise, weight loss, stress reduction, and good sleep hygiene are recommended. For women who cannot or do not want to take HRT, non-hormonal treatments such as fluoxetine, citalopram, or venlafaxine for vasomotor symptoms, vaginal lubricants or moisturizers for vaginal dryness, and cognitive behavior therapy or antidepressants for psychological symptoms can be prescribed.

HRT is a treatment option for women with moderate to severe menopausal symptoms. However, it is contraindicated in women with current or past breast cancer, any estrogen-sensitive cancer, undiagnosed vaginal bleeding, or untreated endometrial hyperplasia. HRT brings certain risks, including venous thromboembolism, stroke, coronary heart disease, breast cancer, and ovarian cancer. Women should be advised of these risks and the fact that symptoms typically last for 2-5 years.

When stopping HRT, it is important to gradually reduce the dosage to limit recurrence of symptoms in the short term. However, in the long term, there is no difference in symptom control. Women who experience ineffective treatment, ongoing side effects, or unexplained bleeding should be referred to secondary care. Overall, managing menopause requires a personalized approach that takes into account a woman’s medical history, preferences, and individual symptoms.

Oligohydramnios is indicated by an amniotic fluid volume of 440ml, while polyhydramnios is associated with tracheo-oesophageal fistula.

Oligohydramnios is a condition characterized by a decrease in the amount of amniotic fluid present in the womb. The definition of oligohydramnios varies, but it is generally considered to be present when there is less than 500ml of amniotic fluid at 32-36 weeks of gestation or an amniotic fluid index (AFI) that falls below the 5th percentile.

There are several potential causes of oligohydramnios, including premature rupture of membranes, Potter sequence, bilateral renal agenesis with pulmonary hypoplasia, intrauterine growth restriction, post-term gestation, and pre-eclampsia. These conditions can all contribute to a reduction in the amount of amniotic fluid present in the womb, which can have significant implications for fetal development and health. It is important for healthcare providers to monitor amniotic fluid levels and identify any potential causes of oligohydramnios in order to provide appropriate care and support for both the mother and the developing fetus.

For the treatment of menorrhagia, the first-line option would be the intrauterine system. Specifically, the Mirena, which contains levonorgestrel, is highly effective in treating menorrhagia and also serves as a long-acting reversible contraceptive. While the combined oral contraceptive pill, tranexamic acid, and mefenamic acid may provide relief from symptoms, they are not the preferred initial treatment. On the other hand, the intrauterine device would not be suitable for addressing this patient’s menorrhagia.

Managing Heavy Menstrual Bleeding

Heavy menstrual bleeding, also known as menorrhagia, is a condition where a woman experiences excessive blood loss during her menstrual cycle. While it was previously defined as total blood loss of over 80 ml per cycle, the management of menorrhagia now depends on the woman’s perception of what is excessive. In the past, hysterectomy was a common treatment for heavy periods, but the approach has changed significantly since the 1990s.

To manage menorrhagia, a full blood count should be performed in all women. If symptoms suggest a structural or histological abnormality, a routine transvaginal ultrasound scan should be arranged. For women who do not require contraception, mefenamic acid or tranexamic acid can be used. If there is no improvement, other drugs can be tried while awaiting referral.

For women who require contraception, options include the intrauterine system (Mirena), combined oral contraceptive pill, and long-acting progestogens. Norethisterone can also be used as a short-term option to rapidly stop heavy menstrual bleeding. The flowchart below shows the management of menorrhagia.

[Insert flowchart here]

To confirm or rule out ectopic pregnancy, the recommended investigation is transvaginal ultrasound. This is because it provides clearer images of the uterus, ovaries, and endometrium, making it more effective in detecting ectopic pregnancies compared to transabdominal scans. While serum Beta-HCG levels are helpful in managing ectopic pregnancies, a single test cannot completely rule out the possibility. Pregnant women are generally advised against undergoing CT scans and abdominal X-rays.

Ectopic pregnancy is a serious condition that requires prompt investigation and management. Women who are stable are typically investigated and managed in an early pregnancy assessment unit, while those who are unstable should be referred to the emergency department. The investigation of choice for ectopic pregnancy is a transvaginal ultrasound, which will confirm the presence of a positive pregnancy test.

There are three ways to manage ectopic pregnancies: expectant management, medical management, and surgical management. The choice of management will depend on various criteria, such as the size of the ectopic pregnancy, whether it is ruptured or not, and the patient’s symptoms and hCG levels. Expectant management involves closely monitoring the patient over 48 hours, while medical management involves giving the patient methotrexate and requires follow-up. Surgical management can involve salpingectomy or salpingotomy, depending on the patient’s risk factors for infertility.

Salpingectomy is the first-line treatment for women with no other risk factors for infertility, while salpingotomy should be considered for women with contralateral tube damage. However, around 1 in 5 women who undergo a salpingotomy require further treatment, such as methotrexate and/or a salpingectomy. It is important to carefully consider the patient’s individual circumstances and make a decision that will provide the best possible outcome.

Starting September 2019, boys in school Year 8 who are 12-13 years old will also be provided with the HPV vaccine, which is currently administered in two doses. Girls receive the second dose within 6-24 months after the first, depending on local guidelines.

The human papillomavirus (HPV) is a known carcinogen that infects the skin and mucous membranes. There are numerous strains of HPV, with the most significant being 6 & 11, which cause genital warts, and 16 & 18, which are linked to various cancers, particularly cervical cancer. HPV infection is responsible for over 99.7% of cervical cancers, and testing for HPV is now a crucial part of cervical cancer screening. Other cancers linked to HPV include anal, vulval, vaginal, mouth, and throat cancers. While there are other risk factors for cervical cancer, such as smoking and contraceptive pill use, HPV is a significant contributor.

In 2008, the UK introduced a vaccination for HPV, initially using Cervarix, which protected against HPV 16 & 18 but not 6 & 11. This decision was criticized due to the significant disease burden caused by genital warts. In 2012, Gardasil replaced Cervarix as the vaccine used, protecting against HPV 6, 11, 16 & 18. Initially given only to girls, boys were also offered the vaccine from September 2019. All 12- and 13-year-olds in school Year 8 are offered the HPV vaccine, which is typically given in school. Parents are informed that their daughter may receive the vaccine against their wishes. The vaccine is given in two doses, with the second dose administered between 6-24 months after the first, depending on local policy. Men who have sex with men under the age of 45 should also be offered the HPV vaccine to protect against anal, throat, and penile cancers. Injection site reactions are common with HPV vaccines.

The recommended treatment for the patient’s likely diagnosis of trichomoniasis is oral metronidazole, either as a 7-day course of 200mg or a one-time dose of 2g. Intramuscular ceftriaxone, benzathine benzylpenicillin, and oral doxycycline are not indicated for the treatment of trichomoniasis. Oral azithromycin is also not effective for this condition.

Understanding Trichomonas vaginalis and its Comparison to Bacterial Vaginosis

Trichomonas vaginalis is a type of protozoan parasite that is highly motile and flagellated. It is known to cause trichomoniasis, which is a sexually transmitted infection. The infection is characterized by symptoms such as offensive, yellow/green, frothy vaginal discharge, vulvovaginitis, and strawberry cervix. The pH level is usually above 4.5, and in men, it may cause urethritis.

To diagnose trichomoniasis, a wet mount microscopy is conducted to observe the motile trophozoites. The treatment for trichomoniasis involves oral metronidazole for 5-7 days, although a one-off dose of 2g metronidazole may also be used.

When compared to bacterial vaginosis, trichomoniasis has distinct differences. Bacterial vaginosis is caused by an overgrowth of bacteria in the vagina, while trichomoniasis is caused by a protozoan parasite. The symptoms of bacterial vaginosis include a thin, grayish-white vaginal discharge with a fishy odor, and a pH level above 4.5. Unlike trichomoniasis, bacterial vaginosis is not considered a sexually transmitted infection.

In conclusion, understanding the differences between trichomoniasis and bacterial vaginosis is crucial in diagnosing and treating these conditions effectively. Proper diagnosis and treatment can help prevent complications and improve overall health and well-being.

A woman with a moderate or high risk of pre-eclampsia, such as this patient who has a family history of pre-eclampsia and type 1 diabetes mellitus, should take aspirin 75-150mg daily from 12 weeks gestation until delivery to reduce the risk of developing pre-eclampsia.

Pre-eclampsia is a condition that occurs during pregnancy and is characterized by high blood pressure, proteinuria, and edema. It can lead to complications such as eclampsia, neurological issues, fetal growth problems, liver involvement, and cardiac failure. Severe pre-eclampsia is marked by hypertension, proteinuria, headache, visual disturbances, and other symptoms. Risk factors for pre-eclampsia include hypertension in a previous pregnancy, chronic kidney disease, autoimmune disease, diabetes, chronic hypertension, first pregnancy, and age over 40. Aspirin may be recommended for women with high or moderate risk factors. Treatment involves emergency assessment, admission for observation, and medication such as labetalol, nifedipine, or hydralazine. Delivery of the baby is the most important step in management, with timing depending on the individual case.

In cases where a pregnant woman is exposed to chickenpox and her immunity status is uncertain, it is recommended to conduct a blood test to check for varicella antibodies. If she is found to be not immune and is over 20 weeks pregnant, either VZIG or aciclovir can be given. However, VZIG is the only option for those under 20 weeks pregnant and not immune. It is important to note that VZIG is effective up to 10 days post-exposure, so there is no need to administer it immediately after the blood test. Prescribing medication without confirming the patient’s immunity status is not recommended. Similarly, reassuring the patient and sending her away without following proper prophylaxis protocol is not appropriate. It is also important to note that the varicella-zoster vaccine is not currently part of the UK’s vaccination schedule and does not play a role in the management of pregnant women.

Chickenpox exposure in pregnancy can pose risks to both the mother and fetus, including fetal varicella syndrome. Post-exposure prophylaxis (PEP) with varicella-zoster immunoglobulin (VZIG) or antivirals should be given to non-immune pregnant women, with timing dependent on gestational age. If a pregnant woman develops chickenpox, specialist advice should be sought and oral aciclovir may be given if she is ≥ 20 weeks and presents within 24 hours of onset of the rash.

To confirm ovulation in patients struggling to conceive, a serum progesterone level should be taken 7 days prior to the expected next period. This timing coincides with ovulation and is the most accurate way to confirm it. Taking the test 14 days before the next expected period or on the first day of the next period would not be timed correctly. It is also important to note that the timing of intercourse does not affect the confirmation of ovulation through serum progesterone testing.

Infertility is a common issue that affects approximately 1 in 7 couples. It is important to note that around 84% of couples who have regular sexual intercourse will conceive within the first year, and 92% within the first two years. The causes of infertility can vary, with male factor accounting for 30%, unexplained causes accounting for 20%, ovulation failure accounting for 20%, tubal damage accounting for 15%, and other causes accounting for the remaining 15%.

When investigating infertility, there are some basic tests that can be done. These include a semen analysis and a serum progesterone test. The serum progesterone test is done 7 days prior to the expected next period, typically on day 21 for a 28-day cycle. The interpretation of the serum progesterone level is as follows: if it is less than 16 nmol/l, it should be repeated and if it remains consistently low, referral to a specialist is necessary. If the level is between 16-30 nmol/l, it should be repeated, and if it is greater than 30 nmol/l, it indicates ovulation.

It is important to counsel patients on lifestyle factors that can impact fertility. This includes taking folic acid, maintaining a healthy BMI between 20-25, and advising regular sexual intercourse every 2 to 3 days. Additionally, patients should be advised to quit smoking and limit alcohol consumption to increase their chances of conceiving.

Intrauterine contraceptive devices include copper IUDs and levonorgestrel-releasing IUS. Both are over 99% effective. The IUD prevents fertilization by decreasing sperm motility, while the IUS prevents endometrial proliferation and thickens cervical mucus. Potential problems include heavier periods with IUDs and initial bleeding with the IUS. There is a small risk of uterine perforation, ectopic pregnancy, and infection. New IUS systems, such as Jaydess® and Kyleena®, have smaller frames and less levonorgestrel, resulting in lower serum levels and different rates of amenorrhea.

At present, the woman is experiencing premature labour, but it is still in its early stages as she is only 3 cm dilated. As a result, tocolytic medication may be used to halt the labour. However, if the labour persists and delivery becomes necessary, steroids will be administered beforehand to aid in the development of the foetal lungs. Antibiotics are unnecessary since there is no evidence of an infection. The Syntocinon injection contains oxytocin, which increases the strength of uterine contractions.

Risks Associated with Prematurity

Prematurity is a condition that poses several risks to the health of newborns. The risk of mortality increases with decreasing gestational age. Premature babies are at risk of developing respiratory distress syndrome, intraventricular haemorrhage, necrotizing enterocolitis, chronic lung disease, hypothermia, feeding problems, infection, jaundice, and retinopathy of prematurity. Retinopathy of prematurity is a significant cause of visual impairment in babies born before 32 weeks of gestation. The cause of this condition is not fully understood, but it is believed that over oxygenation during ventilation can lead to the proliferation of retinal blood vessels, resulting in neovascularization. Screening for retinopathy of prematurity is done in at-risk groups. Premature babies are also at risk of hearing problems.

To ensure the effectiveness of the contraceptive patch, it should be applied to clean, dry skin on a weekly basis for three weeks, followed by a patch-free week to stimulate a withdrawal bleed. However, if the patch change is delayed for more than 48 hours, it is important to change it immediately and use a barrier method of contraception for the next 7 days. In case of unprotected intercourse, emergency contraceptives should be considered.

The Evra patch is the only contraceptive patch that is approved for use in the UK. The patch cycle lasts for four weeks, during which the patch is worn every day for the first three weeks and changed weekly. During the fourth week, the patch is not worn, and a withdrawal bleed occurs.

If a woman delays changing the patch at the end of week one or two, she should change it immediately. If the delay is less than 48 hours, no further precautions are necessary. However, if the delay is more than 48 hours, she should change the patch immediately and use a barrier method of contraception for the next seven days. If she has had unprotected sex during this extended patch-free interval or in the last five days, emergency contraception should be considered.

If the patch removal is delayed at the end of week three, the woman should remove the patch as soon as possible and apply a new patch on the usual cycle start day for the next cycle, even if withdrawal bleeding is occurring. No additional contraception is needed.

If patch application is delayed at the end of a patch-free week, additional barrier contraception should be used for seven days following any delay at the start of a new patch cycle. For more information, please refer to the NICE Clinical Knowledge Summary on combined hormonal methods of contraception.

Azithromycin or erythromycin are appropriate options for treating Chlamydia in a pregnant patient who is allergic to penicillin. In this case, the patient’s NAAT testing confirmed the presence of Chlamydia, but doxycycline is contraindicated due to the patient’s pregnancy. Amoxicillin is not an option due to the patient’s penicillin allergy. Ceftriaxone is not indicated for Chlamydia, and doxycycline is contraindicated in pregnancy. Therefore, azithromycin or erythromycin are the most appropriate treatment options.

Chlamydia is a common sexually transmitted infection caused by Chlamydia trachomatis. It is prevalent in the UK, with approximately 1 in 10 young women affected. The incubation period is around 7-21 days, but many cases are asymptomatic. Symptoms in women include cervicitis, discharge, and bleeding, while men may experience urethral discharge and dysuria. Complications can include epididymitis, pelvic inflammatory disease, and infertility.

Traditional cell culture is no longer widely used for diagnosis, with nuclear acid amplification tests (NAATs) being the preferred method. Testing can be done using urine, vulvovaginal swab, or cervical swab. Screening is recommended for sexually active individuals aged 15-24 years, and opportunistic testing is common.

Doxycycline is the first-line treatment for Chlamydia, with azithromycin as an alternative if doxycycline is contraindicated or not tolerated. Pregnant women may be treated with azithromycin, erythromycin, or amoxicillin. Patients diagnosed with Chlamydia should be offered partner notification services, with all contacts since the onset of symptoms or within the last six months being notified and offered treatment.

Cavernosal blood gas analysis is a crucial investigation for patients presenting with priapism. In this case, the patient has a partially erect, non-painful penis that has persisted for over 4 hours, indicating non-ischaemic priapism. This type of priapism is caused by large volume arterial inflow to the penis from trauma or congenital malformation. Confirming whether the priapism is ischaemic or non-ischaemic through cavernosal blood gas analysis is essential for appropriate management. Ischaemic priapism is a medical emergency that requires aspiration of blood from the cavernosa, while non-ischaemic priapism can be managed with observation initially. In paediatric patients, a doppler ultrasound may be a better alternative to cavernosal blood gases due to the potential trauma of the procedure.

A CT pelvis is not recommended in this case as it would expose the child to unnecessary radiation. Instead, a doppler ultrasound can be used to investigate the arterial/venous blood flow in the penis. A clotting screen may be useful if the patient has a history of bleeding problems or a family history of haemoglobinopathies. However, it should not delay cavernosal blood gas analysis as it is crucial to confirm the type of priapism. Testicular ultrasound is not a useful imaging modality for investigating priapism. If an imaging modality is required to assess penile blood flow, a doppler ultrasound is the preferred option.

Understanding Priapism: Causes, Symptoms, and Management

Priapism is a medical condition characterized by a persistent penile erection that lasts longer than four hours and is not associated with sexual stimulation. There are two types of priapism: ischaemic and non-ischaemic, each with a different pathophysiology. Ischaemic priapism is caused by impaired vasorelaxation, resulting in reduced vascular outflow and trapping of de-oxygenated blood within the corpus cavernosa. Non-ischaemic priapism, on the other hand, is due to high arterial inflow, often caused by fistula formation due to congenital or traumatic mechanisms.

Priapism can affect individuals of all ages, with a bimodal distribution of age at presentation, with peaks between 5-10 years and 20-50 years of age. The incidence of priapism has been estimated at up to 5.34 per 100,000 patient-years. There are various causes of priapism, including idiopathic, sickle cell disease or other haemoglobinopathies, erectile dysfunction medication, trauma, and drug use (both prescribed and recreational).

Patients with priapism typically present acutely with a persistent erection lasting over four hours and pain localized to the penis. A history of haemoglobinopathy or medication use may also be present. Cavernosal blood gas analysis and Doppler or duplex ultrasonography can be used to differentiate between ischaemic and non-ischaemic priapism and assess blood flow within the penis. Treatment for ischaemic priapism is a medical emergency and includes aspiration of blood from the cavernosa, injection of a saline flush, and intracavernosal injection of a vasoconstrictive agent. Non-ischaemic priapism, on the other hand, is not a medical emergency and is usually observed as a first-line option.

Liver Disorders in Pregnancy: Differential Diagnosis

During pregnancy, various liver disorders can occur, each with its own set of symptoms and potential complications. Here are some of the most common liver disorders that can occur during pregnancy and their distinguishing features:

1. Hyperemesis gravidarum: This is the most severe form of nausea and vomiting in pregnancy, which can lead to weight loss, dehydration, and electrolyte imbalances. It is characterised by persistent nausea and vomiting, and may require hospitalisation.

2. Acute fatty liver of pregnancy: This is a rare but serious complication that can occur in the third trimester. It is characterised by microvesicular steatosis in the liver, which can lead to liver insufficiency. Symptoms include malaise, nausea and vomiting, right upper quadrant and epigastric pain, and acute renal failure.

3. Intrahepatic cholestasis of pregnancy: This is the most common pregnancy-related liver disorder, characterised by generalised itching, particularly in the palms and soles, and jaundice. It is caused by hormonal changes and can lead to fetal complications if not treated promptly.

4. Pre-eclampsia: This is a disorder of widespread vascular malfunction that occurs after 20 weeks of gestation. It is characterised by hypertension and proteinuria, with or without oedema.

5. Biliary tract disease: This is a broad spectrum of disorders ranging from asymptomatic gallstones to cholecystitis and choledocholithiasis. Symptoms include biliary colic, inflammation of the gall bladder wall, and obstruction of the common bile duct.

It is important to differentiate between these liver disorders in pregnancy, as each requires a different approach to management and treatment. Consultation with a healthcare provider is recommended for proper diagnosis and management.

Having endometriosis increases the risk of experiencing an ectopic pregnancy. This patient’s symptoms and positive pregnancy test suggest a likely diagnosis of an ectopic pregnancy. Other risk factors for ectopic pregnancy include previous ectopic pregnancy, fallopian tube damage, and IVF. However, multiparity, previous pre-eclampsia, twin pregnancy, and type 2 diabetes mellitus are not associated with an increased risk of ectopic pregnancy.

Understanding Ectopic Pregnancy: Incidence and Risk Factors

Ectopic pregnancy occurs when a fertilized egg implants outside the uterus, usually in the fallopian tubes. This condition is a serious medical emergency that requires immediate attention. According to epidemiological studies, ectopic pregnancy occurs in approximately 0.5% of all pregnancies.

Several risk factors can increase the likelihood of ectopic pregnancy. These include damage to the fallopian tubes due to pelvic inflammatory disease or surgery, a history of previous ectopic pregnancy, endometriosis, the use of intrauterine contraceptive devices (IUCDs), and the progesterone-only pill. In vitro fertilization (IVF) also increases the risk of ectopic pregnancy, with approximately 3% of IVF pregnancies resulting in ectopic implantation.

It is important to note that any factor that slows down the passage of the fertilized egg to the uterus can increase the risk of ectopic pregnancy. Early detection and prompt treatment are crucial in managing this condition and preventing serious complications.

Currently, there is no dependable screening test for detecting ovarian cancer in its early stages. However, women, especially those over 50 years old, who experience persistent symptoms such as abdominal bloating, early satiety, loss of appetite, pelvic or abdominal pain, and increased urinary urgency or frequency should be suspected of having ovarian cancer and should undergo further tests.

Ovarian cancer is a common malignancy in women, ranking fifth in frequency. It is most commonly diagnosed in women over the age of 60 and has a poor prognosis due to late detection. The majority of ovarian cancers, around 90%, are of epithelial origin, with serous carcinomas accounting for 70-80% of cases. Interestingly, recent research suggests that many ovarian cancers may actually originate in the distal end of the fallopian tube. Risk factors for ovarian cancer include a family history of BRCA1 or BRCA2 gene mutations, early menarche, late menopause, and nulliparity.

Clinical features of ovarian cancer are often vague and can include abdominal distension and bloating, abdominal and pelvic pain, urinary symptoms such as urgency, early satiety, and diarrhea. The initial diagnostic test recommended by NICE is a CA125 blood test, although this can also be elevated in other conditions such as endometriosis and benign ovarian cysts. If the CA125 level is raised, an urgent ultrasound scan of the abdomen and pelvis should be ordered. However, a CA125 test should not be used for screening asymptomatic women. Diagnosis of ovarian cancer is difficult and usually requires a diagnostic laparotomy.

Management of ovarian cancer typically involves a combination of surgery and platinum-based chemotherapy. Unfortunately, 80% of women have advanced disease at the time of diagnosis, leading to a 5-year survival rate of only 46%. It was previously thought that infertility treatment increased the risk of ovarian cancer due to increased ovulation, but recent evidence suggests that this is not a significant factor. In fact, the combined oral contraceptive pill and multiple pregnancies have been shown to reduce the risk of ovarian cancer by reducing the number of ovulations.

If a patient’s cervical cancer screening shows a positive result for high-risk HPV (hrHPV) and cytological abnormalities, they should be referred for a colposcopy. This is because HPV increases the risk of developing cervical intraepithelial neoplasia and abnormal cytology indicates the need for further investigation. If the sample is inadequate, a repeat test should be offered in 3 months. However, there is no situation in which a patient is asked to return for a repeat test in 6 months. If the patient is hrHPV negative, they would be returned to normal recall as the NHS now follows an HPV first system. If the patient is hrHPV positive but has normal cytology, they would be invited for a repeat test in 12 months to assess for resolution of HPV or for further increased surveillance before considering a colposcopy. It would be inappropriate to reassure the patient and return them to normal recall if they are hrHPV positive and have dyskaryosis.

The cervical cancer screening program has evolved to include HPV testing, which allows for further risk stratification. A negative hrHPV result means a return to normal recall, while a positive result requires cytological examination. Abnormal cytology results lead to colposcopy, while normal cytology results require a repeat test at 12 months. Inadequate samples require a repeat within 3 months, and two consecutive inadequate samples lead to colposcopy. Treatment for CIN typically involves LLETZ or cryotherapy. Individuals who have been treated for CIN should be invited for a test of cure repeat cervical sample 6 months after treatment.

Barrier Methods of Contraception

Barrier methods of contraception are still commonly used as a means of preventing unintended pregnancies. In addition to preventing pregnancy, condoms also offer some protection against sexually transmitted infections (STIs). The two most popular types of barrier methods used in the UK are condoms and diaphragms/cervical caps.

When used perfectly, male condoms have an efficacy rate of 98%, while female condoms have an efficacy rate of 95%. However, in typical use, the efficacy rates drop to 80% for both male and female condoms. Diaphragms and cervical caps, when used with spermicide, have an efficacy rate of 92-96%.

It is important to note that oil-based lubricants should not be used with latex condoms, as they can weaken the material and increase the risk of breakage. For individuals who are allergic to latex, polyurethane condoms should be used instead. Overall, barrier methods of contraception remain a popular choice for individuals looking to prevent pregnancy and protect against STIs.

The increase in body temperature after ovulation is utilized in certain cases of natural family planning.

Phases of the Menstrual Cycle

The menstrual cycle is a complex process that can be divided into four phases: menstruation, follicular phase, ovulation, and luteal phase. During the follicular phase, a number of follicles develop in the ovaries, with one follicle becoming dominant around the mid-follicular phase. At the same time, the endometrium begins to proliferate. This phase is characterized by a rise in follicle-stimulating hormone (FSH), which results in the development of follicles that secrete oestradiol.

During ovulation, the mature egg is released from the dominant follicle and triggers the acute release of luteinizing hormone (LH). This phase occurs on day 14 of the menstrual cycle. Following ovulation, the luteal phase begins, during which the corpus luteum secretes progesterone. This hormone causes the endometrium to change into a secretory lining. If fertilization does not occur, the corpus luteum will degenerate, and progesterone levels will fall.

The cervical mucus also changes throughout the menstrual cycle. Following menstruation, the mucus is thick and forms a plug across the external os. Just prior to ovulation, the mucus becomes clear, acellular, and low viscosity. It also becomes ‘stretchy’ – a quality termed spinnbarkeit. Under the influence of progesterone, it becomes thick, scant, and tacky.

Basal body temperature is another indicator of the menstrual cycle. It falls prior to ovulation due to the influence of oestradiol and rises following ovulation in response to higher progesterone levels. Understanding the different phases of the menstrual cycle can help individuals track their fertility and plan for pregnancy.

Penile cancer can manifest as an ulcer. The most prevalent form of penile cancer is squamous cell carcinoma, not adenocarcinoma. While stress ulcers cause abdominal pain and bleeding, they are not responsible for this presentation. Herpes outbreaks can be triggered by significant stress, but they typically cause painful lesions that heal within a week. Syphilis, caused by Treponema pallidum, can result in a painless ulcer called a chancre, but it does not cause weight loss, and the lesion usually resolves within six to eight weeks, even without treatment.

Understanding Penile Cancer: Causes, Symptoms, and Treatment

Penile cancer is a rare type of cancer that is typically characterized by squamous cell carcinoma. It is a condition that affects the penis and can cause a variety of symptoms, including penile lump and ulceration. There are several risk factors associated with penile cancer, including human immunodeficiency virus infection, human papillomavirus virus infection, genital warts, poor hygiene, phimosis, paraphimosis, balanitis, and age over 50.

When it comes to treating penile cancer, there are several options available, including radiotherapy, chemotherapy, and surgery. The prognosis for penile cancer can vary depending on the stage of the cancer and the treatment options chosen. However, the overall survival rate for penile cancer is approximately 50% at 5 years.

Couples are advised to engage in regular sexual intercourse every 2-3 days for a period of 12 months before seeking referral to a specialist. After this time, fertility testing should be conducted, including semen analysis for the male and mid-luteal progesterone level for the female to confirm ovulation. The use of basal body temperature kits is not recommended as they can increase anxiety and have not been proven effective. However, early referral should be considered for females over 35 years of age, those with a history of amenorrhea or pelvic surgery, and those with abnormal genital examinations. Males with a history of genital surgery, STIs, varicocele, or significant systemic illness should also be referred early.

Infertility is a common issue that affects approximately 1 in 7 couples. It is important to note that around 84% of couples who have regular sexual intercourse will conceive within the first year, and 92% within the first two years. The causes of infertility can vary, with male factor accounting for 30%, unexplained causes accounting for 20%, ovulation failure accounting for 20%, tubal damage accounting for 15%, and other causes accounting for the remaining 15%.

When investigating infertility, there are some basic tests that can be done. These include a semen analysis and a serum progesterone test. The serum progesterone test is done 7 days prior to the expected next period, typically on day 21 for a 28-day cycle. The interpretation of the serum progesterone level is as follows: if it is less than 16 nmol/l, it should be repeated and if it remains consistently low, referral to a specialist is necessary. If the level is between 16-30 nmol/l, it should be repeated, and if it is greater than 30 nmol/l, it indicates ovulation.

It is important to counsel patients on lifestyle factors that can impact fertility. This includes taking folic acid, maintaining a healthy BMI between 20-25, and advising regular sexual intercourse every 2 to 3 days. Additionally, patients should be advised to quit smoking and limit alcohol consumption to increase their chances of conceiving.

If the 1st repeat smear at 12 months is still positive for high-risk strains of human papillomavirus (hrHPV), the correct course of action is to repeat the smear 12 months later (i.e. at 24 months). Colposcopy is not indicated in this case, as it would only be necessary if this was her 3rd successive annual cervical smear that is still positive for hrHPV but with no cytological abnormalities. Repeating the cervical smear after 3 months is also not necessary, as this is only indicated if the first smear is inadequate. Similarly, repeating the cervical smear in 3 years is not appropriate, as hrHPV has been detected. Repeating the cervical smear after 6 months is also not necessary, as this is usually done as a test of cure following treatment for cervical intraepithelial neoplasia.

The cervical cancer screening program has evolved to include HPV testing, which allows for further risk stratification. A negative hrHPV result means a return to normal recall, while a positive result requires cytological examination. Abnormal cytology results lead to colposcopy, while normal cytology results require a repeat test at 12 months. Inadequate samples require a repeat within 3 months, and two consecutive inadequate samples lead to colposcopy. Treatment for CIN typically involves LLETZ or cryotherapy. Individuals who have been treated for CIN should be invited for a test of cure repeat cervical sample 6 months after treatment.

If enzyme-inducing drugs are taken at the same time as the combined oral contraceptive pill, its effectiveness is decreased. Out of the given choices, only St John’s wort is an enzyme inducer, while the rest are enzyme inhibitors.

Counselling for Women Considering the Combined Oral Contraceptive Pill

Women who are considering taking the combined oral contraceptive pill (COC) should receive counselling on the potential harms and benefits of the pill. The COC is highly effective if taken correctly, with a success rate of over 99%. However, there is a small risk of blood clots, heart attacks, and strokes, as well as an increased risk of breast and cervical cancer.

In addition to discussing the potential risks and benefits, women should also receive advice on how to take the pill. If the COC is started within the first 5 days of the menstrual cycle, there is no need for additional contraception. However, if it is started at any other point in the cycle, alternative contraception should be used for the first 7 days. Women should take the pill at the same time every day and should be aware that intercourse during the pill-free period is only safe if the next pack is started on time.

There have been recent changes to the guidelines for taking the COC. While it was previously recommended to take the pill for 21 days and then stop for 7 days to mimic menstruation, it is now recommended to discuss tailored regimes with women. This is because there is no medical benefit to having a withdrawal bleed, and options include never having a pill-free interval or taking three 21-day packs back-to-back before having a 4 or 7 day break.

Women should also be informed of situations where the efficacy of the pill may be reduced, such as vomiting within 2 hours of taking the pill, medication that induces diarrhoea or vomiting, or taking liver enzyme-inducing drugs. It is also important to discuss sexually transmitted infections and precautions that should be taken with enzyme-inducing antibiotics such as rifampicin.

Overall, counselling for women considering the COC should cover a range of topics to ensure that they are fully informed and able to make an informed decision about their contraceptive options.

Weight gain is a known side effect of the Depo Provera contraceptive method. Additionally, it may take up to a year for fertility to return after discontinuing use, and there is an increased risk of osteoporosis and irregular bleeding. Other contraceptive methods such as the combined pill, progesterone only pill, and subdermal implant do not have a proven link to weight gain.

Injectable Contraceptives: Depo Provera

Injectable contraceptives are a popular form of birth control in the UK, with Depo Provera being the main option available. This contraceptive contains 150mg of medroxyprogesterone acetate and is administered via intramuscular injection every 12 weeks. It can be given up to 14 weeks after the last dose without the need for extra precautions. The primary method of action is by inhibiting ovulation, while secondary effects include cervical mucus thickening and endometrial thinning.

However, there are some disadvantages to using Depo Provera. Once the injection is given, it cannot be reversed, and there may be a delayed return to fertility of up to 12 months. Adverse effects may include irregular bleeding and weight gain, and there is a potential increased risk of osteoporosis. It should only be used in adolescents if no other method of contraception is suitable.

It is important to note that there are contraindications to using Depo Provera, such as current breast cancer (UKMEC 4) or past breast cancer (UKMEC 3). While Noristerat is another injectable contraceptive licensed in the UK, it is rarely used in clinical practice and is given every 8 weeks. Overall, injectable contraceptives can be an effective form of birth control, but it is important to weigh the potential risks and benefits before deciding on this method.

Gonorrhoea is best treated with intramuscular ceftriaxone.

Understanding Gonorrhoea: Causes, Symptoms, Microbiology, and Management

Gonorrhoea is a sexually transmitted infection caused by the Gram-negative diplococcus Neisseria gonorrhoeae. It can occur on any mucous membrane surface, including the genitourinary tract, rectum, and pharynx. The incubation period of gonorrhoea is typically 2-5 days. Symptoms in males include urethral discharge and dysuria, while females may experience cervicitis leading to vaginal discharge. Rectal and pharyngeal infections are usually asymptomatic.

Immunisation against gonorrhoea is not possible, and reinfection is common due to antigen variation of type IV pili and Opa proteins. Local complications may develop, including urethral strictures, epididymitis, and salpingitis, which can lead to infertility. Disseminated infection may also occur, with gonococcal infection being the most common cause of septic arthritis in young adults.

Management of gonorrhoea involves the use of antibiotics. Ciprofloxacin used to be the treatment of choice, but there is now increased resistance to it. Cephalosporins are now more widely used, with a single dose of IM ceftriaxone 1g being the new first-line treatment. If ceftriaxone is refused, oral cefixime 400mg + oral azithromycin 2g should be used. Disseminated gonococcal infection (DGI) and gonococcal arthritis may also occur, with symptoms including tenosynovitis, migratory polyarthritis, and dermatitis. Later complications include septic arthritis, endocarditis, and perihepatitis.

To prevent neural tube defects in the foetus, it is crucial to consume folic acid. It is advised that women who are planning to conceive should take a supplement of 400 micrograms of folic acid daily. This dose should be continued until the 12th week of pregnancy. If there is a family history or a previous pregnancy affected by neural tube defects, the recommended dose should be increased.

Folic Acid: Importance, Deficiency, and Prevention

Folic acid is a vital nutrient that is converted to tetrahydrofolate (THF) in the body. It is found in green, leafy vegetables and plays a crucial role in the transfer of 1-carbon units to essential substrates involved in the synthesis of DNA and RNA. However, certain factors such as phenytoin, methotrexate, pregnancy, and alcohol excess can cause a deficiency in folic acid. This deficiency can lead to macrocytic, megaloblastic anemia and neural tube defects.

To prevent neural tube defects during pregnancy, it is recommended that all women take 400mcg of folic acid until the 12th week of pregnancy. Women at higher risk of conceiving a child with a neural tube defect should take 5mg of folic acid from before conception until the 12th week of pregnancy. Women are considered higher risk if they or their partner has a neural tube defect, they have had a previous pregnancy affected by a neural tube defect, or they have a family history of a neural tube defect. Additionally, women with certain medical conditions such as coeliac disease, diabetes, or thalassaemia trait, or those taking antiepileptic drugs, or who are obese (BMI of 30 kg/m2 or more) are also considered higher risk.

In summary, folic acid is an essential nutrient that plays a crucial role in DNA and RNA synthesis. Deficiency in folic acid can lead to serious health consequences, including neural tube defects. However, taking folic acid supplements during pregnancy can prevent these defects and ensure a healthy pregnancy.

What is the effectiveness of secondary prevention measures for women with pre-eclampsia? A-level research has shown that low-dose aspirin, when started at 12-14 weeks’ gestation, is more effective than a placebo in reducing the occurrence of pre-eclampsia in high-risk women. This treatment also reduces perinatal mortality and the risk of babies being born small for gestational age. While low molecular weight heparin may reduce placental insufficiency in pre-eclampsia, there is currently a lack of long-term safety studies. Labetalol and methyldopa are commonly used antihypertensive drugs for acute management of pre-eclampsia, but they are not given prophylactically and do not reduce intrauterine growth retardation. Unfractionated heparin has also not been proven to prevent the development of uteroplacental insufficiency.

Hypertension during pregnancy is a common occurrence that requires careful management. In normal pregnancies, blood pressure tends to decrease in the first trimester and then gradually increase to pre-pregnancy levels by term. However, in cases of hypertension during pregnancy, the systolic blood pressure is usually above 140 mmHg or the diastolic blood pressure is above 90 mmHg. Additionally, an increase of more than 30 mmHg systolic or 15 mmHg diastolic from the initial readings may also indicate hypertension.

There are three categories of hypertension during pregnancy: pre-existing hypertension, pregnancy-induced hypertension (PIH), and pre-eclampsia. Pre-existing hypertension refers to a history of hypertension before pregnancy or elevated blood pressure before 20 weeks gestation. PIH occurs in the second half of pregnancy and resolves after birth. Pre-eclampsia is characterized by hypertension and proteinuria, and may also involve edema.

The management of hypertension during pregnancy involves the use of antihypertensive medications such as labetalol, nifedipine, and hydralazine. In cases of pre-existing hypertension, ACE inhibitors and angiotensin II receptor blockers should be stopped immediately and alternative medications should be prescribed. Women who are at high risk of developing pre-eclampsia should take aspirin from 12 weeks until the birth of the baby. It is important to carefully monitor blood pressure and proteinuria levels during pregnancy to ensure the health of both the mother and the baby.

Bacterial vaginosis is the identified condition, primarily caused by an overgrowth of anaerobic organisms in the vagina, with Gardnerella vaginalis being the most prevalent. This results in the displacement of lactobacilli, which would not be detected in the sample. The presence of hyphae suggests the existence of Candida (thrush).

Bacterial vaginosis (BV) is a condition where there is an overgrowth of anaerobic organisms, particularly Gardnerella vaginalis, in the vagina. This leads to a decrease in the amount of lactobacilli, which produce lactic acid, resulting in an increase in vaginal pH. BV is not a sexually transmitted infection, but it is commonly seen in sexually active women. Symptoms include a fishy-smelling vaginal discharge, although some women may not experience any symptoms at all. Diagnosis is made using Amsel’s criteria, which includes the presence of thin, white discharge, clue cells on microscopy, a vaginal pH greater than 4.5, and a positive whiff test. Treatment involves oral metronidazole for 5-7 days, with a cure rate of 70-80%. However, relapse rates are high, with over 50% of women experiencing a recurrence within 3 months. Topical metronidazole or clindamycin may be used as alternatives.

Bacterial vaginosis during pregnancy can increase the risk of preterm labor, low birth weight, chorioamnionitis, and late miscarriage. It was previously recommended to avoid oral metronidazole in the first trimester and use topical clindamycin instead. However, recent guidelines suggest that oral metronidazole can be used throughout pregnancy. The British National Formulary (BNF) still advises against using high-dose metronidazole regimes. Clue cells, which are vaginal epithelial cells covered with bacteria, can be seen on microscopy in women with BV.

Endometriosis is characterized by pelvic pain, dysmenorrhoea, dyspareunia, and subfertility. The main indicators of this condition are cyclic abdominal pain and deep dyspareunia, which may be accompanied by fertility issues. Unlike endometriosis, pelvic inflammatory disease does not typically cause pain during menstruation. A bicornuate uterus, which is a congenital anomaly resulting in a heart-shaped uterus, is associated with a higher risk of recurrent miscarriages. Cervical carcinomas are usually accompanied by abnormal bleeding, such as post-coital and inter-menstrual bleeding, but they are unlikely to have been present for as long as three years.

Understanding Endometriosis

Endometriosis is a common condition where endometrial tissue grows outside of the uterus. It affects around 10% of women of reproductive age and can cause chronic pelvic pain, painful periods, painful intercourse, and subfertility. Other symptoms may include urinary problems and painful bowel movements. Diagnosis is typically made through laparoscopy, and treatment options depend on the severity of symptoms.

First-line treatments for symptomatic relief include NSAIDs and/or paracetamol. If these do not help, hormonal treatments such as the combined oral contraceptive pill or progestogens may be tried. If symptoms persist or fertility is a priority, referral to secondary care may be necessary. Secondary treatments may include GnRH analogues or surgery. For women trying to conceive, laparoscopic excision or ablation of endometriosis plus adhesiolysis is recommended, as well as ovarian cystectomy for endometriomas.

It is important to note that there is poor correlation between laparoscopic findings and severity of symptoms, and that there is little role for investigation in primary care. If symptoms are significant, referral for a definitive diagnosis is recommended.

For patients with active hormone-responsive breast cancer, hormonal methods like HRT and tibolone are not recommended. Instead, non-hormonal methods like selective serotonin reuptake inhibitors and venlafaxine may be used to alleviate vasomotor symptoms of menopause. Topical estrogen can also be used to alleviate symptoms of vaginal atrophy, but it does not help with vasomotor symptoms. COCP is not a suitable treatment for menopausal symptoms.

Managing Menopause: Lifestyle Modifications, Hormone Replacement Therapy, and Non-Hormone Replacement Therapy

Menopause is a natural biological process that marks the end of a woman’s reproductive years. It is diagnosed when a woman has not had a period for 12 consecutive months. Menopausal symptoms are common and can last for up to 7 years, with varying degrees of severity and duration. The management of menopause can be divided into three categories: lifestyle modifications, hormone replacement therapy (HRT), and non-hormone replacement therapy.

Lifestyle modifications can help manage menopausal symptoms such as hot flushes, sleep disturbance, mood changes, and cognitive symptoms. Regular exercise, weight loss, stress reduction, and good sleep hygiene are recommended. For women who cannot or do not want to take HRT, non-hormonal treatments such as fluoxetine, citalopram, or venlafaxine for vasomotor symptoms, vaginal lubricants or moisturizers for vaginal dryness, and cognitive behavior therapy or antidepressants for psychological symptoms can be prescribed.

HRT is a treatment option for women with moderate to severe menopausal symptoms. However, it is contraindicated in women with current or past breast cancer, any estrogen-sensitive cancer, undiagnosed vaginal bleeding, or untreated endometrial hyperplasia. HRT brings certain risks, including venous thromboembolism, stroke, coronary heart disease, breast cancer, and ovarian cancer. Women should be advised of these risks and the fact that symptoms typically last for 2-5 years.

When stopping HRT, it is important to gradually reduce the dosage to limit recurrence of symptoms in the short term. However, in the long term, there is no difference in symptom control. Women who experience ineffective treatment, ongoing side effects, or unexplained bleeding should be referred to secondary care. Overall, managing menopause requires a personalized approach that takes into account a woman’s medical history, preferences, and individual symptoms.

Ovulation is caused by the LH surge.

Phases of the Menstrual Cycle

The menstrual cycle is a complex process that can be divided into four phases: menstruation, follicular phase, ovulation, and luteal phase. During the follicular phase, a number of follicles develop in the ovaries, with one follicle becoming dominant around the mid-follicular phase. At the same time, the endometrium begins to proliferate. This phase is characterized by a rise in follicle-stimulating hormone (FSH), which results in the development of follicles that secrete oestradiol.

During ovulation, the mature egg is released from the dominant follicle and triggers the acute release of luteinizing hormone (LH). This phase occurs on day 14 of the menstrual cycle. Following ovulation, the luteal phase begins, during which the corpus luteum secretes progesterone. This hormone causes the endometrium to change into a secretory lining. If fertilization does not occur, the corpus luteum will degenerate, and progesterone levels will fall.

The cervical mucus also changes throughout the menstrual cycle. Following menstruation, the mucus is thick and forms a plug across the external os. Just prior to ovulation, the mucus becomes clear, acellular, and low viscosity. It also becomes ‘stretchy’ – a quality termed spinnbarkeit. Under the influence of progesterone, it becomes thick, scant, and tacky.

Basal body temperature is another indicator of the menstrual cycle. It falls prior to ovulation due to the influence of oestradiol and rises following ovulation in response to higher progesterone levels. Understanding the different phases of the menstrual cycle can help individuals track their fertility and plan for pregnancy.

Bacterial vaginosis (BV) is a common vaginal infection that affects many women, with up to 50% of cases being asymptomatic. The main symptom of BV is a fishy-smelling discharge from the vagina.

In pregnant women, BV can lead to late miscarriage and preterm delivery if left untreated. Therefore, all pregnant women who experience symptoms should receive treatment. This typically involves taking oral metronidazole twice a day for 5-7 days, as a single 2-gram dose is not recommended during pregnancy.

However, for asymptomatic pregnant women with BV, treatment is considered on a case-by-case basis. This is because research suggests that identifying and treating asymptomatic cases does not necessarily reduce the risk of preterm birth. This information is based on guidelines from NICE CKS.

Bacterial vaginosis (BV) is a condition where there is an overgrowth of anaerobic organisms, particularly Gardnerella vaginalis, in the vagina. This leads to a decrease in the amount of lactobacilli, which produce lactic acid, resulting in an increase in vaginal pH. BV is not a sexually transmitted infection, but it is commonly seen in sexually active women. Symptoms include a fishy-smelling vaginal discharge, although some women may not experience any symptoms at all. Diagnosis is made using Amsel’s criteria, which includes the presence of thin, white discharge, clue cells on microscopy, a vaginal pH greater than 4.5, and a positive whiff test. Treatment involves oral metronidazole for 5-7 days, with a cure rate of 70-80%. However, relapse rates are high, with over 50% of women experiencing a recurrence within 3 months. Topical metronidazole or clindamycin may be used as alternatives.

Bacterial vaginosis during pregnancy can increase the risk of preterm labor, low birth weight, chorioamnionitis, and late miscarriage. It was previously recommended to avoid oral metronidazole in the first trimester and use topical clindamycin instead. However, recent guidelines suggest that oral metronidazole can be used throughout pregnancy. The British National Formulary (BNF) still advises against using high-dose metronidazole regimes. Clue cells, which are vaginal epithelial cells covered with bacteria, can be seen on microscopy in women with BV.

Vasectomy: A Simple and Effective Male Sterilisation Method

Vasectomy is a male sterilisation method that has a failure rate of 1 per 2,000, making it more effective than female sterilisation. The procedure is simple and can be done under local anesthesia, with some cases requiring general anesthesia. After the procedure, patients can go home after a couple of hours. However, it is important to note that vasectomy does not work immediately.

To ensure the success of the procedure, semen analysis needs to be performed twice following a vasectomy before a man can have unprotected sex. This is usually done at 12 weeks after the procedure. While vasectomy is generally safe, there are some complications that may arise, such as bruising, hematoma, infection, sperm granuloma, and chronic testicular pain. This pain affects between 5-30% of men.

In the event that a man wishes to reverse the procedure, the success rate of vasectomy reversal is up to 55% if done within 10 years. However, the success rate drops to approximately 25% after more than 10 years. Overall, vasectomy is a simple and effective method of male sterilisation, but it is important to consider the potential complications and the need for semen analysis before engaging in unprotected sex.

When managing an ectopic pregnancy through surgery, it is necessary to administer Anti-D immunoglobulin. However, if the ectopic pregnancy is being treated medically or if the location of the pregnancy is unknown, Anti-D is not needed. The Coombs test has two types: Direct Coombs, which is used to detect autoimmune haemolytic anaemia, and Indirect Coombs, which is used during pregnancy to identify antibodies in the mother’s blood that can cause haemolytic disease in the newborn.

Rhesus negative pregnancies can lead to the formation of anti-D IgG antibodies in the mother if she delivers a Rh +ve child, which can cause haemolysis in future pregnancies. Prevention involves testing for D antibodies and giving anti-D prophylaxis to non-sensitised Rh -ve mothers at 28 and 34 weeks. Anti-D immunoglobulin should be given within 72 hours in various situations. Tests should be done on all babies born to Rh -ve mothers, and affected fetuses may experience various complications and require treatment such as transfusions and UV phototherapy.

Breast Mass Differential Diagnosis

Breast abscesses typically present with localised breast inflammation, pain, and fever. Treatment involves antibiotics and/or incision and drainage. Early breast cancer may be asymptomatic, but may present with changes in breast size or shape, skin dimpling, nipple abnormalities, and axillary lump. Fat necrosis is a benign inflammatory process that can result from trauma or surgery, and presents as a firm, painless mass. Fibroadenoma is the most common cause of breast mass in women aged <35 years, presenting as a singular, firm, rubbery, smooth, mobile, painless mass. Diffuse cystic mastopathy is characterised by cysts of varying sizes due to hormonal changes, but typically presents with multiple lumps and is not associated with inflammation. Clinical examination and biopsy may be needed to differentiate between these conditions.

For pregnant women who are at moderate or high risk of pre-eclampsia, it is recommended to take aspirin in low doses of 75-150mg daily from 12 weeks of gestation until delivery. In this case, the patient has three moderate risk factors for pre-eclampsia and should be advised to take low-dose aspirin throughout her pregnancy. While hydralazine is an alternative antihypertensive medication to labetalol in pregnancy, it is not necessary for this patient as she is not hypertensive. Labetalol is the first-line antihypertensive medication for pregnant women. Magnesium is only indicated for severe pre-eclampsia to prevent or treat seizures in patients with eclampsia, which is not present in this patient.

Pre-eclampsia is a condition that occurs during pregnancy and is characterized by high blood pressure, proteinuria, and edema. It can lead to complications such as eclampsia, neurological issues, fetal growth problems, liver involvement, and cardiac failure. Severe pre-eclampsia is marked by hypertension, proteinuria, headache, visual disturbances, and other symptoms. Risk factors for pre-eclampsia include hypertension in a previous pregnancy, chronic kidney disease, autoimmune disease, diabetes, chronic hypertension, first pregnancy, and age over 40. Aspirin may be recommended for women with high or moderate risk factors. Treatment involves emergency assessment, admission for observation, and medication such as labetalol, nifedipine, or hydralazine. Delivery of the baby is the most important step in management, with timing depending on the individual case.

After giving birth, women need to use contraception only after 21 days.

As the woman in the question is only 14 days post-partum, she does not need emergency contraception. Therefore, the advice to her would be that emergency contraception is not necessary.

After giving birth, women need to use contraception after 21 days. The progestogen-only pill (POP) can be started at any time postpartum, according to the FSRH. Additional contraception should be used for the first two days after day 21. A small amount of progestogen enters breast milk, but it is not harmful to the infant. On the other hand, the combined oral contraceptive pill (COCP) is absolutely contraindicated (UKMEC 4) if breastfeeding is less than six weeks post-partum. If breastfeeding is between six weeks and six months postpartum, it is a UKMEC 2. The COCP may reduce breast milk production in lactating mothers. It should not be used in the first 21 days due to the increased venous thromboembolism risk post-partum. After day 21, additional contraception should be used for the first seven days. The intrauterine device or intrauterine system can be inserted within 48 hours of childbirth or after four weeks.

The lactational amenorrhoea method (LAM) is 98% effective if the woman is fully breastfeeding (no supplementary feeds), amenorrhoeic, and less than six months post-partum. It is important to note that an inter-pregnancy interval of less than 12 months between childbirth and conceiving again is associated with an increased risk of preterm birth, low birth weight, and small for gestational age babies.

Understanding Genital Warts

Genital warts, also known as condylomata accuminata, are a common reason for visits to genitourinary clinics. These warts are caused by various types of the human papillomavirus (HPV), with types 6 and 11 being the most common culprits. It is important to note that HPV, particularly types 16, 18, and 33, can increase the risk of cervical cancer.

The warts themselves are small, fleshy protrusions that are typically 2-5mm in size and may be slightly pigmented. They can cause discomfort, itching, and even bleeding. Treatment options for genital warts include topical podophyllum or cryotherapy, depending on the location and type of lesion. Topical agents are generally used for multiple, non-keratinised warts, while solitary, keratinised warts respond better to cryotherapy. Imiquimod, a topical cream, is often used as a second-line treatment. It is important to note that genital warts can be resistant to treatment, and recurrence is common. However, most anogenital HPV infections clear up on their own within 1-2 years without intervention.

Post-menopausal women often experience atrophic vaginitis, which is characterized by symptoms such as vaginal dryness, dyspareunia, and occasional spotting. During examination, the vagina may appear dry and pale. Treatment options include the use of vaginal lubricants and moisturizers. If these prove ineffective, topical oestrogen cream may be prescribed.

Atrophic vaginitis is a condition that commonly affects women who have gone through menopause. Its symptoms include vaginal dryness, pain during sexual intercourse, and occasional spotting. Upon examination, the vagina may appear dry and pale. The recommended treatment for this condition is the use of vaginal lubricants and moisturizers. If these do not provide relief, a topical estrogen cream may be prescribed.

GnRH agonists can be effective in reducing the size of uterine fibroids, but their use is typically limited to short-term treatment. It is important to note that these agonists are primarily used to decrease the size of the uterus prior to surgery, as the risk of post-operative blood loss is directly related to the size of the uterus. Progesterone receptor inhibitors, on the other hand, do not have an impact on overall uterine size and are therefore not useful in preparing for surgery. However, they can be helpful in reducing the severity of fibroid-related bleeding. It is also important to avoid taking COCP 4-6 weeks prior to major surgery due to an increased risk of venous thromboembolism, and to avoid antiplatelet drugs such as Ibuprofen before surgery. While antifibrinolytics like tranexamic acid can be useful in reducing the severity of uterine bleeding, they are not helpful in preparing for surgery.

Understanding Uterine Fibroids

Uterine fibroids are non-cancerous growths that develop in the uterus. They are more common in black women and are thought to occur in around 20% of white women in their later reproductive years. Fibroids are usually asymptomatic, but they can cause menorrhagia, which can lead to iron-deficiency anaemia. Other symptoms include lower abdominal pain, bloating, and urinary symptoms. Fibroids may also cause subfertility.

Diagnosis is usually made through transvaginal ultrasound. Asymptomatic fibroids do not require treatment, but periodic monitoring is recommended. Menorrhagia secondary to fibroids can be managed with various treatments, including the levonorgestrel intrauterine system, NSAIDs, tranexamic acid, and hormonal therapies.

Medical treatment to shrink or remove fibroids may include GnRH agonists or ulipristal acetate, although the latter is not currently recommended due to concerns about liver toxicity. Surgical options include myomectomy, hysteroscopic endometrial ablation, hysterectomy, and uterine artery embolization.

Fibroids generally regress after menopause, but complications such as subfertility and iron-deficiency anaemia can occur. Red degeneration, which is haemorrhage into the tumour, is a common complication during pregnancy.

The Mirena coil is a contraceptive method that reduces the duration and intensity of periods and can be used for an extended period.

Intrauterine contraceptive devices include copper IUDs and levonorgestrel-releasing IUS. Both are over 99% effective. The IUD prevents fertilization by decreasing sperm motility, while the IUS prevents endometrial proliferation and thickens cervical mucus. Potential problems include heavier periods with IUDs and initial bleeding with the IUS. There is a small risk of uterine perforation, ectopic pregnancy, and infection. New IUS systems, such as Jaydess® and Kyleena®, have smaller frames and less levonorgestrel, resulting in lower serum levels and different rates of amenorrhea.

The use of COCP is absolutely contraindicated for individuals who are over 35 years old and smoke more than 15 cigarettes per day. Migraine without aura is not a contraindication, but migraine with aura is a UKMEC 3 contraindication. A BMI of over 35 kg/m2 and a family history of thromboembolism at age less than 45 years are also UKMEC 3 contraindications, but in this case, the patient’s BMI is 25 kg/m2 and her mother had pulmonary embolism at the age of 60 years, so these are not contraindications. Breastfeeding less than 6 weeks post-partum is a UKMEC 4 contraindication, but since the patient is 10 weeks post-partum, it is a UKMEC 2.

The decision to prescribe the combined oral contraceptive pill is now based on the UK Medical Eligibility Criteria (UKMEC), which categorizes potential contraindications and cautions on a four-point scale. UKMEC 1 indicates no restrictions for use, while UKMEC 2 suggests that the benefits outweigh the risks. UKMEC 3 indicates that the disadvantages may outweigh the advantages, and UKMEC 4 represents an unacceptable health risk. Examples of UKMEC 3 conditions include controlled hypertension, a family history of thromboembolic disease in first-degree relatives under 45 years old, and current gallbladder disease. Examples of UKMEC 4 conditions include a history of thromboembolic disease or thrombogenic mutation, breast cancer, and uncontrolled hypertension. Diabetes mellitus diagnosed over 20 years ago is classified as UKMEC 3 or 4 depending on severity. In 2016, breast feeding between 6 weeks and 6 months postpartum was changed from UKMEC 3 to UKMEC 2.

Contraceptives – Time to become effective (if not used on the first day of period):
Immediate: IUD
2 days: Progestin-only pill (POP)
7 days: Combined oral contraceptive (COC), injection, implant, intrauterine system (IUS)

Intrauterine contraceptive devices include copper IUDs and levonorgestrel-releasing IUS. Both are over 99% effective. The IUD prevents fertilization by decreasing sperm motility, while the IUS prevents endometrial proliferation and thickens cervical mucus. Potential problems include heavier periods with IUDs and initial bleeding with the IUS. There is a small risk of uterine perforation, ectopic pregnancy, and infection. New IUS systems, such as Jaydess® and Kyleena®, have smaller frames and less levonorgestrel, resulting in lower serum levels and different rates of amenorrhea.

For the treatment of genital warts, topical podophyllum is recommended for multiple, non-keratinised warts, while cryotherapy is recommended for solitary, keratinised warts. Cryotherapy can also be used as an initial treatment for genital warts.

Understanding Genital Warts

Genital warts, also known as condylomata accuminata, are a common reason for visits to genitourinary clinics. These warts are caused by various types of the human papillomavirus (HPV), with types 6 and 11 being the most common culprits. It is important to note that HPV, particularly types 16, 18, and 33, can increase the risk of cervical cancer.

The warts themselves are small, fleshy protrusions that are typically 2-5mm in size and may be slightly pigmented. They can cause discomfort, itching, and even bleeding. Treatment options for genital warts include topical podophyllum or cryotherapy, depending on the location and type of lesion. Topical agents are generally used for multiple, non-keratinised warts, while solitary, keratinised warts respond better to cryotherapy. Imiquimod, a topical cream, is often used as a second-line treatment. It is important to note that genital warts can be resistant to treatment, and recurrence is common. However, most anogenital HPV infections clear up on their own within 1-2 years without intervention.

For women with no other risk factors for infertility, salpingectomy is the first-line treatment for ectopic pregnancy requiring surgical management, rather than salpingotomy. In the case of a patient with acute-onset abdominal pain and vaginal bleeding after 6-8 weeks following her last period, a positive pregnancy test, and ultrasound findings confirming an ectopic pregnancy, laparoscopic salpingectomy and monitoring is the correct course of action. This is especially true if the size of the ectopic pregnancy is greater than 35 mm and the beta-hCG levels are higher than 5000 IU/L. Salpingotomy may require further treatment with methotrexate and may not remove the ectopic pregnancy entirely, making salpingectomy the preferred method. Expectant management and monitoring, laparoscopic salpingotomy and monitoring, and methotrexate and monitoring are all inappropriate for this patient’s case.

Ectopic pregnancy is a serious condition that requires prompt investigation and management. Women who are stable are typically investigated and managed in an early pregnancy assessment unit, while those who are unstable should be referred to the emergency department. The investigation of choice for ectopic pregnancy is a transvaginal ultrasound, which will confirm the presence of a positive pregnancy test.

There are three ways to manage ectopic pregnancies: expectant management, medical management, and surgical management. The choice of management will depend on various criteria, such as the size of the ectopic pregnancy, whether it is ruptured or not, and the patient’s symptoms and hCG levels. Expectant management involves closely monitoring the patient over 48 hours, while medical management involves giving the patient methotrexate and requires follow-up. Surgical management can involve salpingectomy or salpingotomy, depending on the patient’s risk factors for infertility.

Salpingectomy is the first-line treatment for women with no other risk factors for infertility, while salpingotomy should be considered for women with contralateral tube damage. However, around 1 in 5 women who undergo a salpingotomy require further treatment, such as methotrexate and/or a salpingectomy. It is important to carefully consider the patient’s individual circumstances and make a decision that will provide the best possible outcome.

Prescribing the combined oral contraceptive pill is not recommended for women with a family history of breast cancer associated with a BRCA mutation. However, for those with a family history of breast cancer but no BRCA mutation, the contraceptive pill is considered safe and has no restrictions (UKMEC 1). Therefore, if a patient with this medical history requests the combined oral contraceptive pill, it should be prescribed to her as the preferred contraceptive method.

The decision to prescribe the combined oral contraceptive pill is now based on the UK Medical Eligibility Criteria (UKMEC), which categorizes potential contraindications and cautions on a four-point scale. UKMEC 1 indicates no restrictions for use, while UKMEC 2 suggests that the benefits outweigh the risks. UKMEC 3 indicates that the disadvantages may outweigh the advantages, and UKMEC 4 represents an unacceptable health risk. Examples of UKMEC 3 conditions include controlled hypertension, a family history of thromboembolic disease in first-degree relatives under 45 years old, and current gallbladder disease. Examples of UKMEC 4 conditions include a history of thromboembolic disease or thrombogenic mutation, breast cancer, and uncontrolled hypertension. Diabetes mellitus diagnosed over 20 years ago is classified as UKMEC 3 or 4 depending on severity. In 2016, breast feeding between 6 weeks and 6 months postpartum was changed from UKMEC 3 to UKMEC 2.

Gynaecomastia may be linked to each of the remaining four drugs instead of galactorrhoea.

Understanding Prolactin and Galactorrhoea

Prolactin is a hormone produced by the anterior pituitary gland, and its release is regulated by various physiological factors. Dopamine is the primary inhibitor of prolactin release, and dopamine agonists like bromocriptine can be used to manage galactorrhoea. Galactorrhoea is a condition characterized by the production of breast milk in individuals who are not breastfeeding. It is important to distinguish the causes of galactorrhoea from those of gynaecomastia, which is the enlargement of male breast tissue.

Excess prolactin can lead to different symptoms in men and women. Men may experience impotence, loss of libido, and galactorrhoea, while women may have amenorrhoea and galactorrhoea. Several factors can cause raised prolactin levels, including prolactinoma, pregnancy, oestrogens, stress, exercise, sleep, acromegaly, polycystic ovarian syndrome, and primary hypothyroidism. Additionally, certain medications like metoclopramide, domperidone, phenothiazines, haloperidol, SSRIs, and opioids can also increase prolactin levels.

In summary, understanding prolactin and its effects on the body is crucial in diagnosing and managing conditions like galactorrhoea. Identifying the underlying causes of raised prolactin levels is essential in providing appropriate treatment and improving patient outcomes.

Postpartum haemorrhage caused by uterine atony can be treated with various medical options such as oxytocin, ergometrine, carboprost and misoprostol.

Uterine atony is the primary cause of postpartum haemorrhage, which occurs when the uterus fails to contract fully after the delivery of the placenta, leading to difficulty in achieving haemostasis. This condition is often associated with overdistension, which can be caused by multiple gestation, macrosomia, polyhydramnios or other factors.

In addition to the standard approach for managing PPH, including an ABC approach for unstable patients, the following steps should be taken in sequence:

1. Bimanual uterine compression to stimulate contraction manually
2. Intravenous oxytocin and/or ergometrine
3. Intramuscular carboprost
4. Intramyometrial carboprost
5. Rectal misoprostol
6. Surgical intervention such as balloon tamponade

(RCOG Green-top Guideline No. 52)

Understanding Postpartum Haemorrhage

Postpartum haemorrhage (PPH) is a condition where a woman experiences blood loss of more than 500 ml after giving birth vaginally. It can be classified as primary or secondary. Primary PPH occurs within 24 hours after delivery and is caused by the 4 Ts: tone, trauma, tissue, and thrombin. The most common cause is uterine atony. Risk factors for primary PPH include previous PPH, prolonged labour, pre-eclampsia, increased maternal age, emergency Caesarean section, and placenta praevia.

In managing PPH, it is important to involve senior staff immediately and follow the ABC approach. This includes two peripheral cannulae, lying the woman flat, blood tests, and commencing a warmed crystalloid infusion. Mechanical interventions such as rubbing up the fundus and catheterisation are also done. Medical interventions include IV oxytocin, ergometrine, carboprost, and misoprostol. Surgical options such as intrauterine balloon tamponade, B-Lynch suture, ligation of uterine arteries, and hysterectomy may be considered if medical options fail to control the bleeding.

Secondary PPH occurs between 24 hours to 6 weeks after delivery and is typically due to retained placental tissue or endometritis. It is important to understand the causes and risk factors of PPH to prevent and manage this life-threatening emergency effectively.

Patients with secondary dysmenorrhoea require referral to gynaecology for investigation, including this patient who exhibits such symptoms. While tranexamic acid is effective for menorrhagia, it is not useful for dysmenorrhoea. While a transvaginal ultrasound scan may be part of the investigation, a specialist review is more crucial, particularly for this patient who displays symptoms indicative of endometriosis, which may not be visible on an ultrasound scan. Before using the intrauterine system or combined oral contraceptive pill to treat endometriosis, a diagnosis is necessary.

Dysmenorrhoea is a condition where women experience excessive pain during their menstrual period. There are two types of dysmenorrhoea: primary and secondary. Primary dysmenorrhoea affects up to 50% of menstruating women and is not caused by any underlying pelvic pathology. It usually appears within 1-2 years of the menarche and is thought to be partially caused by excessive endometrial prostaglandin production. Symptoms include suprapubic cramping pains that may radiate to the back or down the thigh, and pain typically starts just before or within a few hours of the period starting. NSAIDs such as mefenamic acid and ibuprofen are effective in up to 80% of women, and combined oral contraceptive pills are used second line for management.

Secondary dysmenorrhoea, on the other hand, typically develops many years after the menarche and is caused by an underlying pathology. The pain usually starts 3-4 days before the onset of the period. Causes of secondary dysmenorrhoea include endometriosis, adenomyosis, pelvic inflammatory disease, intrauterine devices, and fibroids. Clinical Knowledge Summaries recommend referring all patients with secondary dysmenorrhoea to gynaecology for investigation. It is important to note that the intrauterine system (Mirena) may help dysmenorrhoea, but this only applies to normal copper coils.

For symptomatic men with Chlamydia, it is recommended to notify all sexual partners from the 4 weeks prior to the onset of symptoms. As for women and asymptomatic men, all sexual partners from the last 6 months or the most recent partner should be notified. Pregnant women should undergo a test of cure (TOC) 6 weeks after infection, according to BASHH guidelines. Performing a TOC earlier than 6 weeks may result in a false positive due to the presence of nonviable Chlamydia DNA on the NAAT. However, uncomplicated Chlamydia infection in men and non-pregnant women does not require a routine TOC.

Chlamydia is a common sexually transmitted infection caused by Chlamydia trachomatis. It is prevalent in the UK, with approximately 1 in 10 young women affected. The incubation period is around 7-21 days, but many cases are asymptomatic. Symptoms in women include cervicitis, discharge, and bleeding, while men may experience urethral discharge and dysuria. Complications can include epididymitis, pelvic inflammatory disease, and infertility.

Traditional cell culture is no longer widely used for diagnosis, with nuclear acid amplification tests (NAATs) being the preferred method. Testing can be done using urine, vulvovaginal swab, or cervical swab. Screening is recommended for sexually active individuals aged 15-24 years, and opportunistic testing is common.

Doxycycline is the first-line treatment for Chlamydia, with azithromycin as an alternative if doxycycline is contraindicated or not tolerated. Pregnant women may be treated with azithromycin, erythromycin, or amoxicillin. Patients diagnosed with Chlamydia should be offered partner notification services, with all contacts since the onset of symptoms or within the last six months being notified and offered treatment.

Understanding Vulval Carcinoma

Vulval carcinoma is a type of cancer that affects the vulva, which is the external female genitalia. It is a relatively rare condition, with only around 1,200 cases diagnosed in the UK each year. The majority of cases occur in women over the age of 65 years, and around 80% of cases are squamous cell carcinomas.

There are several risk factors associated with vulval carcinoma, including human papilloma virus (HPV) infection, vulval intraepithelial neoplasia (VIN), immunosuppression, and lichen sclerosus. Symptoms of vulval carcinoma may include a lump or ulcer on the labia majora, inguinal lymphadenopathy, and itching or irritation.

It is important for women to be aware of the risk factors and symptoms of vulval carcinoma, and to seek medical attention if they experience any concerning symptoms. Early detection and treatment can improve outcomes and increase the chances of a full recovery.

Breast masses are a common concern among women, and it is important to understand the possible causes to determine the appropriate course of action. Here are some of the most common causes of breast masses and their characteristics:

Fibroadenoma: This is the most common cause of breast mass in women under 35 years old. It appears as a singular, firm, rubbery, smooth, mobile, painless mass ranging in size from 1 cm to 5 cm. Ultrasonography reveals a well-defined, hypoechoic, homogeneous mass 1–20 cm in diameter.

Fat Necrosis: This is a benign inflammatory process that occurs when there is saponification of local fat. It can result from direct trauma or nodular panniculitis. The breast mass is usually firm, round, and painless, and there may be a single mass or multiple masses. It may be tender or painful in some people.

Breast Abscess: This usually presents with localised breast oedema, erythema, warmth, and pain. There may be associated symptoms of fever, nausea, vomiting, spontaneous drainage from the mass or nipple, and a history of previous breast infection.

Breast Cancer: Early breast cancer may be asymptomatic, and pain and discomfort are typically not present. It is often first detected as an abnormality on a mammogram before it is felt by the patient or healthcare professional. If a lump is discovered, there may be a change in breast size or shape, skin dimpling or skin changes, recent nipple inversion or skin change, or nipple abnormalities.

Lipoma: Lipomas are common benign tumors composed of mature adipocytes that typically present clinically as well-circumscribed, soft, mobile, nontender masses. The classic mammographic appearance of lipoma is a circumscribed fat-containing mass.

It is important to note that the physical examination findings may not always be enough to determine the cause of the breast mass, and further testing may be necessary. Consultation with a healthcare professional is recommended for proper diagnosis and treatment.

When taken correctly, the pill is an effective method of preventing pregnancy, but it cannot prevent implantation if taken after engaging in unprotected sexual intercourse.

Emergency contraception is available in the UK through two methods: emergency hormonal contraception and intrauterine device (IUD). Emergency hormonal contraception includes two types of pills: levonorgestrel and ulipristal. Levonorgestrel works by stopping ovulation and inhibiting implantation, while ulipristal primarily inhibits ovulation. Levonorgestrel should be taken as soon as possible after unprotected sexual intercourse, within 72 hours, and is 84% effective when used within this time frame. The dose should be doubled for those with a BMI over 26 or weight over 70kg. Ulipristal should be taken within 120 hours of intercourse and may reduce the effectiveness of hormonal contraception. The most effective method of emergency contraception is the copper IUD, which can be inserted within 5 days of unprotected intercourse or up to 5 days after the likely ovulation date. It may inhibit fertilization or implantation and is 99% effective regardless of where it is used in the cycle. Prophylactic antibiotics may be given if the patient is at high risk of sexually transmitted infection.